Holmes Tremor Partially Responsive to Topiramate: A Case Report
Background: Holmes tremor is a rare symptomatic movement disorder, characterized by a combination of resting, postural, and intention tremor. It is usually caused by lesions in the brainstem, thalamus, and cerebellum. Despite pharmacological advances, its treatment remains a challenge; many medications have been used with various degrees of effectiveness. Stereotactic thalamotomy and deep brain stimulation in the ventralis intermedius nucleus have been effective surgical procedures in cases refractory to medical treatment.
Case Report: Here we report a young woman with topiramate-responsive Holmes tremor secondary to a brainstem cavernoma.
Discussion: Herein we report a Holmes tremor responsive to Topiramate.
Keywords: Holmes tremor, topiramate
Citation: González Rojas N, Cesarini M, Etcheverry JL, Da Prat G, Viera Aramburu T, Gatto EM. Holmes tremor partially responsive to topiramate: a case report. Tremor Other Hyperkinet Mov. 2018; 8. doi: 10.7916/D82C0FFN
*To whom correspondence should be addressed. E-mail: email@example.com
Editor: Elan D. Louis, Yale University, USA
Received: April 9, 2018 Accepted: May 31, 2018 Published: June 26, 2018
Copyright: © 2018 Rojas et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original authors and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.
Financial Disclosures: None.
Conflicts of Interest: The authors report no conflict of interest.
Ethics Statement: All patients that appear on video have provided written informed consent; authorization for the videotaping and for publication of the videotape was provided.
Holmes tremor (HT) is characterized by a combination of resting, postural, and intention tremor and is usually caused by injuries involving the brainstem, thalamus, cerebellum, or their connections.1
The current definition is derived from the consensus statement of the Movement Disorder Society on Tremor from 2018.2 It is described as a syndrome of rest, postural, and intention tremor that usually appears from proximal and distal rhythmic muscle contraction at low frequency (<5 Hz). The etiology is frequently an acquired lesion in the brainstem in the vicinity of the red nucleus. The different etiologies include ischemic or hemorrhagic cerebrovascular disorders, bleeding because of vascular malformations, head trauma, tumors, demyelination, or infections.3–5
Tremor commonly develops between 1 and 24 months after a central nervous system insult. This delayed onset might be due to neuronal plastic changes.6–9 HT usually occurs with other localizing signs, but is rarely isolated.10
The treatment is often challenging and only few cases of treatment-responsive HT have been reported in the literature.15 Here, we report a patient diagnosed with a brainstem cavernoma who developed HT responsive to topiramate (TPM).
A 33-year-old right-handed female, without any relevant medical history, suffered a sudden left hemiparesis on January 2016. Brain magnetic resonance imaging (MRI) showed a brainstem hemorrhage, involving the right mesencephalon, secondary to an extensive cavernous angioma, with diencephalic and thalamic extension (Figures 1 and 2). Repeated hemorrhages lead to a space-occupying lesion. She underwent surgery for the hematoma evacuation, but complete resection was not possible. A few weeks later, she developed a rest tremor, worsening with posture and additionally intensified with action involving her left arm. The tremor seriously affected the patient’s daily activities and quality of life. Several drugs were tried, including pramipexole extended release 3 mg once a day, levodopa/carbidopa 250/25 mg four times a day, valproic acid 500 mg twice a day, levetiracetam 1 g twice a day, quetiapine 50 mg twice a day, gabapentin 600 mg twice a day, clonazepam 2 mg twice a day, and agomelatine 50 mg once a day, all of them titrated to maximum doses, without tremor improvement. Deep brain stimulation (DBS) and thalamotomy were excluded because of the high risk of procedure-related complications. On September 2017, she was admitted to our center; neurological examination showed a left spastic hemiparesis with brisk deep tendon reflexes and a left severe resting, postural, and intention tremor. The patient’s consent was obtained prior to recording the video (Video 1). The basal Fahn–Tolosa–Marin Tremor Rating Scale scored 76 points (range, parts A + B + C = 0–156). She marked the intensity of tremor as 9 out of 10 using the visual analog scale (VAS).
Basal Holmes Tremor. Segment 1A. Standing position, showing a rest tremor on the left upper limb that worsens with posture and even more with action. A right palpebral ptosis can also be seen. Segment 1B. Sitting position, showing how the left lower limb is also involved to a lesser extent with a rest tremor.
After other drugs were discontinued, TPM was started at a dose of 25 mg and titrated to 100 mg (50 mg twice a day). A tremor improvement was observed at the highest dose (Video 2), allowing her to be partially independent in the daily living activities, with no negative impact on the emotional or cognitive sphere. At these doses, the Fahn–Tolosa–Marin Tremor Rating Scale scored 41 points (53% improvement) and 5 out of 10 on VAS.
HT, midbrain tremor, or rubral tremor was first described in 1904 by Gordon Holmes. It is a symptomatic, low frequency (<4.5 Hz) tremor that predominantly affects the proximal limbs. Some authors hypothesized that the delayed tremor onset after lesion could be explained by a rearrangement of central pathways in the brain or an aberrant result of plasticity.16 The HT treatment is a challenge with moderate or poor response.17–20 Benzodiazepines, propranolol, anticholinergics, channel-blockers, anticonvulsants (lamotrigine, levetiracetam, valproic acid, zonisamide, gabapentin, carbamazepine), atypical neuroleptics (quetiapine, clozapine), baclofen, dopamine agonists (bromocriptine, pramipexole, piribedil), and L-dopa are among the drugs with a variable success.21 Although, the number of cases reported in the literature is small, L-dopa was the leading one with a substantial outcome.22–24 This observation is in order with the proposed functional deficit of nigrostriatal dopaminergic pathway.25,26
However, satisfactory clinical improvement following treatment with L-dopa is not achieved in some patients, as in our case, and other oral medications, botulinum toxin injections,27,28 or several surgical procedures are required.29,30
TPM, an antiepileptic drug that was originally designed as an oral hypoglycemic and subsequently approved as an anticonvulsant, is also effective in reducing essential tremor (ET).
To the best of our knowledge, the present case is the first report of TPM-responsive HT. After an extensive search in the literature, we found the use of TPM in one HT patient of a series reported by Raina et al.33 but in this case TPM was included in the group of drugs with poor or no response. Despite these controversial findings and the lack of evidence, extensive research is still warranted to determine the effectiveness of TPM in HT.34,35
In summary, in this patient, with a contraindication for surgical approach36,37 (DBS or thalamic lesion) and lack of responsiveness to various drugs, including L-dopa, TPM may be a useful drug to improve HT with moderate benefits (about 50 % of tremor scales).
The authors would like to thank the patient for her participation and collaboration.
1. Holmes G. On certain tremors in organic cerebral lesions. Brain 1904;27:327–375. doi: 10.1093/brain/27.3.327
2. Bhatia K, Bain P, Bajaj N, Elble RJ, Hallett M, Louis ED, et al. Consensus statement on the classification of tremors, from the Task Force on Tremor of the International Parkinson and Movement Disorder Society. Mov Disord 2018;33:75–87. doi: 10.1002/mds.27121
3. Gajos A, Bogucki A, Schinwelski M, Sołtan W, Rudzińska M, Budrewicz S, et al. The clinical and neuroimaging studies in Holmes tremor. Acta Neurol Scand 2010;122:360–366. doi: 10.1111/j.1600-0404.2009.01319.x
4. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Mov Disord 1998;13(Suppl. 3):2–23. doi: 10.1002/mds.870131303
5. Choi SM. Movement disorders following cerebrovascular lesions in cerebellar circuits. Mov Disord 2016;9:80–88. doi: 10.14802/jmd.16004
6. Krack P, Deuschl G, Kaps M, Warnke P, Schneider S, Traupe H. Delayed onset of ‘rubral tremor’ 23 years after brainstem trauma. Mov Disord 1994;9:240–242. doi: 10.1002/mds.870090225
7. Martins WA, Porcello Marrone LC, Fussiger H, Vedana VM, do Amaral Cristovam R, Taietti MZ, et al. Holmes’ tremor as a delayed complication of thalamic stroke. Clin Neurosci 2016;26:158–159. doi: 10.1016/j.jocn.2015.09.014
8. Krystkowiak P, Martinat P, Cassim F, Pruvo JP, Leys D, Guieu JD, et al. Thalamic tremor: correlations with three-dimensional magnetic resonance imaging data and pathophysiological mechanisms. Mov Disord 2000;15:911–918. doi: 10.1002/1531-8257(200009)15:5<911::AID-MDS1023>3.0.CO;2-B
9. Vidailhet M, Jedynak CP, Pollak P, Agid Y. Pathology of symptomatic tremors. Mov Disord 1998;13:49–54. doi: 10.1002/mds.870131309
10. Cho C, Samkoff LM. A lesion of the anterior thalamus producing dystonic tremor of the hand. Arch Neurol 2000;57:1353–1355. doi: 10.1001/archneur.57.9.1353
11. Zhong J, Shi-ting L, Shun-qing X, Liang W. Case report: Holmes’ tremor caused by midbrain cavernoma. Chinese Med J 2007;120:2059–2061.
12. Guedj E, Witjas T, Azulay JP, de Laforte C, Peragut JC, Mundler O. Neuroimaging findings in a case of Holmes tremor. Clin Nucl Med 2007;32:139–140. doi: 10.1097/01.rlu.0000251948.30673.4f
13. Sławek J, Szymkiewicz-Rogowska A, Friedman A. Rubral tremor of Holmes, rare case of pathological tremor: case report. Neurol Neurochir Pol 2000;34:775–782.
14. Paviour DC, Jäger HR, Wilkinson L, Jahanshahi M, Lees AJ. Holmes tremor: application of modern neuroimaging techniques. Mov Disord 2006;21:2260–2262. doi: 10.1002/mds.20981
15. Alqwaifly M. Treatment responsive Holmes tremor: case report and literature review. Int J Health Sci 2016;10:558–562.
16. Miwa H, Hatori K, Kondo T, Imai H, Mizuno Y. Thalamic tremor: case reports and implications of the tremor-generating mechanism. Neurology 1996;46:75–79. doi: 10.1212/WNL.46.1.75
17. Suda S, Yamazaki M, Katsura K, Fukuchi T, Kaneko N, Ueda M, et al. Dramatic response to zonisamide of post-subarachnoid hemorrhage Holmes’ tremor. Neurol 2012;259:185–187. doi: 10.1007/s00415-011-6127-5
18. Ferlazzo E, Morgante F, Rizzo V, Sciarrone G, Meduri M, Magaudda A, et al. Successful treatment of Holmes tremor by levetiracetam. Mov Disord 2008;23:2101–2103. doi: 10.1002/mds.22230
19. Striano P, Elefante A, Coppola A, Tortora F, Zara F, Minetti C, et al. Dramatic response to levetiracetam in post-ischaemic Holmes’ tremor. Neurol Neurosurg Psychiatry 2007;78:438–439. doi: 10.1136/jnnp.2006.103275
20. Streckera K, Schneiderb JP, Sabric O, Wegnera F, Then Bergha F, Schwarza J, et al. Responsiveness to a dopamine agent in Holmes tremor – case report. Eur J Neurol 2007;14:e9–e10. doi: 10.1111/j.1468-1331.2006.01665.x
21. Puschmann A, Wszolek ZK. Diagnosis and treatment of common forms of tremor. Semin Neurol 2011;31:65–77. doi: 10.1055/s-0031-1271312
22. Boelmans K, Gerloff C, Münchau A. Long-lasting effect of levodopa on Holmes’ tremor. Mov Disord 2012;27:1097–1098. doi: 10.1002/mds.24005
23. Harmon RL, Long DF, Shirtz J. Treatment of posttraumatic midbrain resting-kinetic tremor with combined levodopa/carbidopa and carbamazepine. Brain Inj 1991;5:213–218. doi: 10.3109/02699059109008092
24. Katschnig-Winter P, Koegl-Wallner M, Pendl T, Fazekas F, Schwingenschuh P. Levodopa responsive Holmes tremor caused by a single inflammatory demyelinating lesion. Tremor Other Hyperkinet Mov 2015;5. doi: 10.7916/D8WQ033X
25. Remy P, de Recondo A, Defer G, Loc’h C, Amarenco P, Planté-Bordeneuve V, et al. Peduncular “rubral” tremor and dopaminergic denervation: a PET study. Neurology 1995;45:472–477. doi: 10.1212/WNL.45.3.472
26. Schreuder FH, Hamers RM, van Domburg PH. Teaching neuroimages: Holmes tremor after midbrain stroke. Neurology 2010;75:e10. doi: 10.1212/WNL.0b013e3181ea1545
27. Latino P, Pontieri FE, Orzi F, Giovannelli M. Botulinum toxin type A for Holmes tremor secondary to thalamic hemorrhage. Neurol Sci 2015;36:1935–1936. doi: 10.1007/s10072-015-2285-z
28. Ahn SY, Kim DA, Park YO, Shin JH. Effect of ultrasonography-guided botulinum toxin type A injection in Holmes’ tremor secondary to pontine hemorrhage: case report. Ann Rehabil Med 2014;38:694–697. doi: 10.5535/arm.2014.38.5.694
29. Espinoza Martinez JA, Arango GJ, Fonoff ET, Reithmeier T, Escobar OA, Furlanetti L, et al. DBS of the globus pallidus internus or ventralis intermedius nucleus of thalamus for Holmes tremor. Neurosurg Rev 2015;38:753–763. doi: 10.1007/s10143-015-0636-0
30. Aydin S, Abuzayed B, Kiziltan G, Gunduz A, Yagci S. Unilateral thalamic Vim and GPi stimulation for the treatment of Holmes’ tremor caused by midbrain cavernoma: case report and review of the literature. Neurol Surg A Cent Eur Neurosurg 2013;74:271–276. doi: 10.1055/s-0032-1322549
31. Li GJ, Gu H, Guo WJ, Zhang YL, Wang Y, Qiao YJ. Discovery of topiramate’s new functions based on medicinal property combinations and study on its mechanism. Zhongguo Zhong Yao Za Zhi 2014;39:2396–2399.
32. Simeone TA, Wilcox KS, White HS. Subunit selectivity of topiramate modulation of heteromeric GABA(A) receptors. Neuropharmacology 2006;50:845–857. doi: 10.1016/j.neuropharm.2005.12.006
33. Raina GB, Cersosimo MG, Folgar SS, Giugni JC, Calandra C, Paviolo JP, et al. Holmes tremor: clinical description, lesion localization, and treatment in a series of 29 cases. Neurology 2016;86:931–938. doi: 10.1212/WNL.0000000000002440
34. Regragui W, Lachhab L, Razine R, Ait benhaddou EH, Benomar A, Yahyaoui M. A clinical study of non-parkinsonian tremor in Moroccan patients. Revue Neurologique 2014;170:26–31. doi: 10.1016/j.neurol.2013.06.006
35. Zeuner KE, Deuschl G. An update on tremors. Curr Opin Neurol 2012;25:475–482. doi: 10.1097/WCO.0b013e3283550c7e
36. Deuschl G, Bain P. Deep brain stimulation for tremor [correction of trauma]: patient selection and evaluation. Mov Disord 2002;17(Suppl. 3):S102–111. doi: 10.1002/mds.10150
37. Abosch A, Lozano A. Stereotactic neurosurgery for movement disorders. Can J Neurol Sci 2003;30(Suppl. 1):S72–82. doi: 10.1017/S0317167100003279
Figure 1. Brain MRI. ADC (Apparent diffusion coefficient) and FLAIR (fluid-attenuated inversion recovery) sequences showing a right lesion located at the mesencephalon with diencephalic extension.
Figure 2. Brain MRI, Post-gadolinium Images. T2 and T1 sequences enhanced after the administration of gadolinium.
Video 1. Basal Holmes Tremor. Segment 1A. Standing position, showing a rest tremor on the left upper limb that worsens with posture and even more with action. A right palpebral ptosis can also be seen. Segment 1B. Sitting position, showing how the left lower limb is also involved to a lesser extent with a rest tremor.
Video 2. Treatment Response. Segment 2A. Sitting position, showing a decrease in the three components of tremor with predominance of the resting and postural component. Segment 2B. Walking, showing a decrease in the rest component in both the upper and the lower left limbs.